Lupin introduces generic ophthalmic solution in US
The company will start selling its product in US with 180 days of marketing exclusivity.
New Delhi, October 7, 2013: Lupin has launched the generic version of Allergan Inc's Zymaxid Ophthalmic Solution in the US market with 180 days of marketing exclusivity. The company said in a statement that Lupin Pharmaceuticals Inc (LPI), the company's US subsidiary, has launched its generic Gatifloxacin Ophthalmic Solution 0.5 per cent in the US market, after having received the USFDA's final approval.
The company also said that Lupin was the first applicant to file an abbreviated new drug application (ANDA) for Zymaxid Ophthalmic Solution and hence, will be entitled to 180 days of marketing exclusivity.
It may be noted here that the company has been focusing on less competitive specialities spaces in the US market covering segments like oral contraceptives, ophthalmology and dermatology. The company has so far done over 10 filings with the USFDA for ophthalmological products.